Scientists test 'One-Two Punch' to supercharge Cancer-Fighting cells

This study is testing a combination treatment for adults with an aggressive type of B-cell lymphoma that has come back or not responded to standard treatments. The approach has three parts: first, patients receive CAR-T cell therapy, where their own immune cells are modified to attack cancer. Then, they take two maintenance drugs (chidamide and a PD-1 inhibitor) to try to help those cells last longer and work better. The main goal is to see if this strategy can keep the cancer from progressing for at least one year.